Bednarik P. “The Hidden Symptoms of MS: Cognitive Changes.” The Motivator. Winter/Spring 2013.

Cohen JA, et al. “Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.” Neurol. 2002;59(5)679-687.

Confavreux C, Vukusic S, Moreau T, Adeleine P. “Relapses and progression of disability in multiple sclerosis.” N Engl J Med. 2000;343:1430-1438.

Courtney SW, Franco M. “Imagine the Possibilities: An Introduction to Guided Imagery and Its Potential Benefits for Individuals with MS.” MSAA online wellness article at

Courtney SW, Schapiro RT, Barone DA. “Highlights from the AAN and CMSC Annual Meetings [2016].” MSAA online news article at

Dalgas U, Stenager E, Jalobsen J, et al. “Resistance training in MS improves muscle strength and functional capacity in MS.” Neurol. 2009;73(18):1478-1484.

Fabian M. “Highlights from the AAN and CMSC 2017 Annual Meetings.” MSAA online news article at

Fabian M, Krieger S. MS Research Update 2017. Published by MSAA, May 2017.

Freedman MS, et al. “A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.” Neurol. 2011;77(16):1551-1560.

Franco M. “The Emotional and Psychological Symptoms of MS: Anxiety in MS: Frequently Overlooked and Undetected.” The Motivator. Winter/Spring 2014.

Franco M. “The Emotional and Psychological Symptoms of MS: Depressive Disorders.” The Motivator. Winter/Spring 2014.

Hartung HP, et al. “Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial.” Lancet. 2002; 360(9350):2018-2025.

Hawker K, et al. “Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.” Ann Neurol. 2009 Oct;66(4):460-71. doi: 10.1002/ana.21867.

Healy BC, Ali EN, Guttman CR, et al. “Smoking is associated with progression in multiple sclerosis.” Arch Neurol. 2009;66:858-864.

Hommes OR, et al. “Intravenous immunoglobulin in secondary progressivemultiple sclerosis: a randomized placebocontrolled trial.” Lancet. 2004;364(9440):1149-1156.

Hunsberger MB, “Health and Wellness: Enjoying the Benefits of Yoga.” MSAA online wellness article at

Kappos, et al. “Placebo controlled multicenter randomized trial of interferon beta-1b in treatment of secondary progressive MS.” Lancet. 1998; 352(9139):1491-1497.

Koch M, Kingwell E, Rieckmann P, Tremlett H. “The natural history of primary progressive multiple sclerosis.” Neurol. 2009;73:1996-2002.

Krieger SC, et al. “The topographical model of multiple sclerosis: a dynamic visualization of disease course.” Neurol Neuroimmunol Neuroinflamm. 2016.

Li DK, et al. “Randomized controlled trial of interferon beta-1a in secondary progressive MS. MRI results.” Neurol. 2001;56(11):1505-1513.

Maloni HW. “The Hidden Symptoms of MS: Pain with MS.” The Motivator. Winter/Spring 2013.

Miller D, et al. “Study design and baseline characteristics of the INFORMS study: fingolimod in patients with primary progressive MS.” Neurol. 2013.

Namey MA. “Managing the Physical Symptoms of MS: Bladder and Bowel Problems.” The Motivator. Summer/Fall 2013.

Norris C. “Employment Strategies.” MSAA online wellness article at

Noseworthy JH, et al. “Linomide in relapsing and secondary progressive multiple sclerosis: part I: trial design and clinical results.” Neurol. 2000;54(9)1726-1733.

Pohlau D, et al. “Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicenter study.” Mult Scler. 2007;13(9):1107-1117.

Provance PG. “Managing the Physical Symptoms of MS: Mobility and Ambulation.” The Motivator. Summer/Fall 2013.

Rampello A, et al. “Effect of aerobic training on walking capacity and maximal exercise tolerance in patients with multiple sclerosis: A randomized cross-over control study.” Phys Ther. 2007;87(5):545-549.

Rice GP, et al. “Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial.” Neurol. 2000;54(5):1145-1155.

Rintell D. “The Hidden Symptoms of MS: Coping with Fatigue.” The Motivator. Winter/Spring 2013.

Schapiro RT. “Managing the Physical Symptoms of MS: Spasticity.” The Motivator. Summer/Fall 2013.

Tremlett H, Paty D, Devonshire V. “Disability Progression in multiple sclerosis is slower than previously reported.” Neurol. 2006;66: 172-177.

Weiner HL, et al. “Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.” Mult Scler. 2002;8(2):142-154.

Weinshenker BG, Bass B, Rice GP, et al. “The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability.” Brain. 1989; 112 (Pt 1): 133-146.

Wolinskey JS, et al. “Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.” Ann Neurol. 2007;61(1):14-24.

Zajicek J, et al. “Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomized placebo controlled trial.” Lancet Neurol. 2013;12(9):857-865.

Previous: Part III: Healthy Living with Progressive MS | Table of Contents